primari
caus
sever
acut
respiratori
syndrom
sar
newli
discov
coronaviru
replic
sar
coronaviru
scv
occur
mainli
lower
respiratori
tract
caus
diffus
alveolar
damag
lack
understand
pathogenesi
sar
prevent
ration
develop
therapi
diseas
show
extens
scv
antigen
express
type
pneumocyt
experiment
infect
cynomolgu
macaqu
macaca
fasciculari
postinfect
dpi
indic
cell
type
primari
target
scv
infect
earli
diseas
explain
subsequ
pulmonari
damag
also
show
prophylact
treatment
scvinfect
macaqu
antivir
agent
pegyl
significantli
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
compar
untreat
macaqu
postexposur
treatment
pegyl
yield
intermedi
result
therefor
suggest
pegyl
protect
type
pneumocyt
scv
infect
consid
candid
drug
sar
therapi
sar
recent
emerg
human
popul
potenti
fatal
respiratori
diseas
sever
affect
patient
develop
acut
respiratori
distress
syndrom
correspond
diffus
alveolar
damag
dad
autopsi
newli
discov
coronaviru
scv
identifi
primari
caus
sar
sar
patient
treat
empir
combin
ribavirin
oseltamivir
antibiot
corticosteroid
howev
neither
casecontrol
studi
anim
model
use
determin
efficaci
drug
choic
evalu
potenti
drug
also
hamper
poor
understand
pathogenesi
sar
previous
hypothes
scv
infect
type
pneumocyt
base
charact
pulmonari
lesion
experiment
infect
macaqu
known
tropism
respiratori
coronavirus
type
pneumocyt
found
extens
type
pneumocyt
hyperplasia
lung
scvinfect
macaqu
dpi
suggest
loss
type
pneumocyt
earlier
stage
infect
determin
whether
type
pneumocyt
infect
scv
earlier
stage
infect
conduct
patholog
immunohistochem
examin
lung
four
scvinfect
macaqu
control
group
dpi
lung
multifoc
acut
dad
character
flood
alveoli
proteinrich
edema
fluid
mix
neutrophil
rare
syncytia
extens
loss
alveolar
bronchiolar
epithelium
occasion
type
pneumocyt
hyperplasia
fig
comparison
normal
alveolar
morpholog
seen
fig
immunohistochemistri
reveal
extens
scv
antigen
express
squamou
cell
line
alveolar
wall
fig
compar
fig
cell
identifi
type
pneumocyt
locat
morpholog
express
keratin
serial
section
transmiss
electron
microscopi
alveolar
cell
reveal
coronaviruslik
particl
measur
nm
diamet
typic
intern
nucleocapsidlik
structur
fig
g
cell
identifi
type
pneumocyt
line
alveolar
lumen
close
appos
basement
membran
squamou
contain
abund
pinocytot
vesicl
andin
contrast
type
pneumocyteshad
neither
lamellar
bodi
microvilli
found
previous
experiment
infect
macaqu
dpi
less
extens
scv
antigen
express
also
detect
hyperplast
type
pneumocyt
within
inflammatori
foci
fig
togeth
histopatholog
immunohistochem
find
show
type
pneumocyt
main
target
scv
earli
infect
associ
dad
effect
antivir
agent
treatment
scv
infect
need
decreas
viral
replic
first
phase
sar
may
reduc
sever
subsequ
patholog
damag
found
anoth
model
viralinduc
dad
may
inhibit
replic
anim
human
coronavirus
candid
drug
test
efficaci
pegyl
recombin
regist
drug
treatment
chronic
hepat
c
primari
caus
sever
acut
respiratori
syndrom
sar
newli
discov
coronaviru
replic
sar
coronaviru
scv
occur
mainli
lower
respiratori
tract
caus
diffus
alveolar
damag
lack
understand
pathogenesi
sar
prevent
ration
develop
therapi
diseas
show
extens
scv
antigen
express
type
pneumocyt
experiment
infect
cynomolgu
macaqu
macaca
fasciculari
postinfect
dpi
indic
cell
type
primari
target
scv
infect
earli
diseas
explain
subsequ
pulmonari
damag
also
show
prophylact
treatment
scvinfect
macaqu
antivir
agent
pegyl
significantli
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
compar
untreat
macaqu
postexposur
treatment
pegyl
yield
intermedi
result
therefor
suggest
pegyl
protect
type
pneumocyt
scv
infect
consid
candid
drug
sar
therapi
sar
recent
emerg
human
popul
potenti
fatal
respiratori
diseas
sever
affect
patient
develop
acut
respiratori
distress
syndrom
correspond
diffus
alveolar
damag
dad
autopsi
newli
discov
coronaviru
scv
identifi
primari
caus
sar
sar
patient
treat
empir
combin
ribavirin
oseltamivir
antibiot
corticosteroid
howev
neither
casecontrol
studi
anim
model
use
determin
efficaci
drug
choic
evalu
potenti
drug
also
hamper
poor
understand
pathogenesi
sar
previous
hypothes
scv
infect
type
pneumocyt
base
charact
pulmonari
lesion
experiment
infect
macaqu
known
tropism
respiratori
coronavirus
type
pneumocyt
found
extens
type
pneumocyt
hyperplasia
lung
scvinfect
macaqu
dpi
suggest
loss
type
pneumocyt
earlier
stage
infect
determin
whether
type
pneumocyt
infect
scv
earlier
stage
infect
conduct
patholog
immunohistochem
examin
lung
four
scvinfect
macaqu
control
group
dpi
lung
multifoc
acut
dad
character
flood
alveoli
proteinrich
edema
fluid
mix
neutrophil
rare
syncytia
extens
loss
alveolar
bronchiolar
epithelium
occasion
type
pneumocyt
hyperplasia
fig
comparison
normal
alveolar
morpholog
seen
fig
immunohistochemistri
reveal
extens
scv
antigen
express
squamou
cell
line
alveolar
wall
fig
compar
fig
cell
identifi
type
pneumocyt
locat
morpholog
express
keratin
serial
section
transmiss
electron
microscopi
alveolar
cell
reveal
coronaviruslik
particl
measur
nm
diamet
typic
intern
nucleocapsidlik
structur
fig
g
cell
identifi
type
pneumocyt
line
alveolar
lumen
close
appos
basement
membran
squamou
contain
abund
pinocytot
vesicl
andin
contrast
type
pneumocyteshad
neither
lamellar
bodi
microvilli
found
previous
experiment
infect
macaqu
dpi
less
extens
scv
antigen
express
also
detect
hyperplast
type
pneumocyt
within
inflammatori
foci
fig
togeth
histopatholog
immunohistochem
find
show
type
pneumocyt
main
target
scv
earli
infect
associ
dad
effect
antivir
agent
treatment
scv
infect
need
decreas
viral
replic
first
phase
sar
may
reduc
sever
subsequ
patholog
damag
found
anoth
model
viralinduc
dad
may
inhibit
replic
anim
human
coronavirus
candid
drug
test
efficaci
pegyl
recombin
regist
drug
treatment
chronic
hepat
c
chose
drug
regist
therefor
directli
avail
human
recombin
ifn
inhibit
scv
replic
vitro
first
test
effect
pegyl
scvinfect
vero
cell
observ
dosedepend
antivir
effect
fig
determin
plasma
level
pegyl
intramuscular
inject
group
six
macaqu
prophylact
group
high
plasma
level
attain
inject
fig
similar
peak
level
found
patient
subcutan
inject
pegyl
known
activ
macrophag
measur
plasma
level
neopterin
pegyl
treatment
measur
macrophag
activ
neopterin
level
increas
anim
fig
confirm
biolog
avail
pegyl
treat
macaqu
evalu
prophylact
use
pegyl
experiment
infect
macaqu
prophylact
group
scv
start
pegyl
treatment
compar
virolog
patholog
paramet
control
group
four
macaqu
treat
pb
limit
investig
pharyng
swab
lung
earlier
studi
provid
evid
extens
viral
replic
organ
found
paramet
significantli
p
reduc
prophylact
group
compar
control
group
viru
excret
pharynx
abrog
fig
viru
titer
lung
dpi
significantli
p
reduc
fig
immunohistochemistri
show
express
scv
antigen
type
pneumocyt
reduc
fig
patholog
extent
sever
dad
reduc
fig
data
indic
prophylact
use
pegyl
substanti
although
complet
protect
type
pneumocyt
experiment
infect
macaqu
scv
infect
abrog
viru
excret
reduc
sever
pulmonari
lesion
test
efficaci
pegyl
antivir
agent
postexposur
inject
pegyl
intramuscularli
postexposur
group
four
macaqu
experiment
scv
infect
evalu
way
prophylact
group
excret
scv
pharynx
found
dpi
significantli
p
reduc
level
compar
control
group
fig
moreov
viru
titer
lung
dpi
significantli
p
decreas
wherea
remain
paramet
less
reduc
fig
result
show
use
pegyl
postexposur
protect
type
pneumocyt
experiment
infect
macaqu
scv
infect
less
effect
prophylact
use
studi
shown
type
pneumocyt
main
target
cell
scv
infect
cynomolgu
macaqu
earli
diseas
pegyl
protect
type
pneumocyt
scv
infect
first
pointtyp
pneumocyt
primari
target
celli
evid
extens
presenc
scv
type
pneumocyt
dpi
fig
target
type
pneumocyt
scv
explain
clinic
diseas
lesion
center
lower
respiratori
tract
fit
lesion
earli
fatal
sar
case
human
experiment
infect
macaqu
euthan
dpi
ref
patholog
studi
human
macaqu
examin
togeth
follow
tempor
sequenc
lung
lesion
emerg
viral
infect
subsequ
loss
type
pneumocyt
acut
dad
character
flood
alveolar
lumina
highli
proteinac
edema
fluid
chronic
dad
character
type
pneumocyt
hyperplasia
sever
case
extens
pulmonari
fibrosi
sequenc
event
correspond
stereotyp
alveolar
reaction
acut
lung
injuri
varieti
caus
detail
experiment
studi
need
identifi
possibl
target
cell
elucid
pathogenesi
sar
second
pointthat
pegyl
protect
type
pneumocyt
scv
infectioni
base
benefici
effect
pegyl
therapi
initi
scv
inocul
macaqu
macaqu
scv
infect
type
pneumocyt
sever
lung
lesion
significantli
reduc
fig
viral
excret
abrog
fig
pegyl
treatment
may
import
influenc
outcom
sar
virusinduc
toxininduc
dad
sever
pulmonari
damag
dose
depend
higher
dose
caus
increas
pulmonari
fibrosi
loss
lung
function
mortal
reduct
viral
load
pegyl
therapi
earli
stage
scv
infect
might
therefor
help
prevent
seriou
fatal
outcom
sar
associ
pulmonari
fibrosi
addit
potenti
diseas
mitig
reduc
viral
excret
pegyl
therapi
may
also
epidemiolog
effect
reduc
spread
scv
human
popul
whether
mechan
pegyl
protect
direct
antivir
activ
immunostimulatori
effect
remain
determin
reduc
protect
type
pneumocyt
pegyl
postexposur
group
compar
prophylact
group
probabl
initi
therapi
dpi
close
peak
viral
infect
lung
dpi
fig
thu
substanti
infect
type
pneumocyt
may
alreadi
occur
time
pegyl
reach
therapeut
level
vivo
find
accord
reduc
vitro
activ
scv
ad
infect
compar
ad
infect
also
correspond
result
ifn
therapi
acut
viru
infect
anim
model
ifn
effect
administ
viru
inocul
peak
viru
replic
target
organ
time
interv
effect
postexposur
treatment
pegyl
initi
may
longer
human
experiment
infect
macaqu
peak
scv
infect
lung
occur
around
dpi
humansbas
averag
incub
period
ref
peak
viral
excret
onset
symptom
compar
dpi
macaqu
fig
conclus
studi
show
type
pneumocyt
main
target
cell
scv
infect
macaqu
earli
diseas
pegyl
commerci
avail
antivir
drug
protect
cell
scv
infect
believ
preliminari
result
warrant
clinic
studi
pegyl
sar
reemerg
prophylact
earli
postexposur
treatment
pegyl
may
help
reduc
impact
scv
infect
healthcar
worker
other
possibl
expos
scv
may
limit
spread
viru
human
popul
median
tissu
cultur
infecti
dose
tcid
well
scv
obtain
patient
die
sar
h
supernat
remov
cell
fix
neutralbuff
formalin
ethanol
min
room
temperatur
scv
antigenposit
cell
visual
immunohistochemistri
describ
number
scvinfect
cell
per
well
summar
mean
sd
macaqu
studi
approv
anim
experi
obtain
institut
anim
welfar
committe
three
group
cynomolgu
macaqu
infect
intratrach
tcid
scv
suspend
ml
pb
control
group
n
inject
intramuscularli
pb
prophylact
n
postexposur
n
group
treat
pegyl
dose
mgkg
prophylact
group
inject
pegyl
day
scv
infect
postexposur
group
inject
day
scv
infect
four
macaqu
group
euthan
day
infect
day
anesthet
macaqu
ketamin
collect
ml
blood
inguin
vein
took
pharyng
swab
place
ml
transport
medium
pharyng
swab
frozen
rtpcr
analysi
pegyl
level
determin
use
elisa
bender
medsystem
diagnost
pegintron
standard
neopterin
level
determin
describ
necropsi
done
accord
standard
protocol
one
lung
monkey
inflat
neutralbuff
formalin
intrabronchi
intub
suspend
neutralbuff
formalin
overnight
sampl
collect
standard
manner
one
cranial
part
lung
one
medial
part
two
caudal
part
embed
paraffin
cut
use
immunohistochemistri
see
stain
h
e
semiquantit
assess
scv
infectionassoci
inflamm
lung
h
estain
section
examin
inflammatori
foci
light
microscopi
use
object
focu
score
size
smaller
equal
area
object
larger
area
object
smaller
equal
area
object
larger
area
object
sever
inflamm
mild
moder
mark
cumul
score
inflammatori
foci
provid
total
score
per
anim
section
examin
without
knowledg
ident
macaqu
lung
section
one
monkey
postexposur
group
assess
presenc
inflamm
premortem
aspir
food
remain
lung
sampl
control
macaqu
use
transmiss
electron
microscopi
describ
three
lung
tissu
sampl
taken
lung
one
cranial
part
lung
one
medial
part
one
caudal
part
homogen
ml
transport
medium
use
polytron
tissu
grinder
kinematica
lowspe
centrifug
homogen
frozen
inocul
vero
cell
cultur
tenfold
serial
dilut
ident
isol
viru
confirm
scv
rtpcr
supernat
immunohistochemistri
formalinfix
paraffinembed
lung
sampl
use
histologyon
cranial
part
lung
one
medial
part
two
caudal
partwer
cut
stain
scv
antigen
use
either
biotinyl
purifi
human
igg
convalesc
sar
patient
negativecontrol
biotinyl
purifi
human
igg
dilut
buffer
describ
previous
twentyf
arbitrarili
chosen
object
field
lung
parenchyma
lung
section
examin
light
microscopi
presenc
scv
antigen
express
without
knowledg
ident
macaqu
cumul
score
anim
express
number
posit
field
per
field
select
lung
section
macaqu
control
group
stain
monoclon
antibodi
cytokeratin
neomark
identif
epitheli
cell
accord
standard
immunohistochem
procedur
scv
rtpcr
rtpcr
primer
probe
specif
nucleoprotein
gene
scv
use
quantifi
scv
swab
describ
serial
dilut
scv
stock
use
standard
result
express
scv
equival
per
ml
swab
medium
statist
analysi
data
compar
use
student
ttest
antivir
activ
pegyl
scv
vitro
biolog
activ
macaqu
oneway
anova
dunnett
multiplecomparison
test
effect
pegyl
scv
excret
scv
replic
viral
antigen
express
histolog
lesion
lung
differ
consid
signific
p
